3
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Imported COVID-19 Cases Pose New Challenges for China

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear editor, Recently, a letter in your journal predicted the trend of the spread of the novel coronavirus disease 2019 (COVID-19) in China, an illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 1 , 2 would end after March 20, 2020. 3 Currently, the COVID-19 has spread around the globe, with the center of the epidemic shifting from China to Europe and the United States. 4 As of March 24, 2020, a total of 372,757 cases have been confirmed worldwide, with a death toll of 16,231 (WHO, Coronavirus disease 2019 Situation Report 64, March 24, 2020). Italy, in particular, had thus far diagnosed 63,927 patients, 6077 of whom had lost their lives. That translates to a mortality rate of 9.51%, which is more than twice as high as that of China's 4.02% (3283/81,747). The greater share of elderly patients with confirmed COVID-19 infection in Italy along with the population's significantly higher median age may partly explain the differences in cases and case-fatality rates between the two nations. 5 Countries such as the United States (42,164 cases), Spain (33,089 cases), Germany (29,212 cases), and France (19,615 cases) have seen an explosive increase in confirmed cases, with the rate of growth showing no hint of slowing down. For China—the initial epicenter of the outbreak—two stages of the epidemic have passed (Figure 1 A). The first stage is the outbreak period (December 31, 2019 to February 29, 2020), which entailed the period from the first detection of cases to the peak of the epidemic which saw a rapid increase in the number of confirmed cases, and to the time when the growth rate slowed down to less than 200 new confirmed cases per day. In the second stage, which lasted from March 1, 2020 to March 21, 2020, the number of existing cases in most Chinese provinces was reduced to less than 10, respectively, whilst the number of newly confirmed cases in Wuhan, Hubei province, the worst-hit city, was slowly approaching zero. It was during this stage—more specifically on the March 4—that foreign imported cases to appear. During these two stages, the Chinese government, its populous, and its medical professionals had managed to stabilized the deadly epidemic with great deliberation and sacrifices. 6 Currently, however, the situation in China has entered its third stage—recontamination through close contact with foreign infection, as demonstrated by the emergence of second-generation case originated from imported cases first reported in Guangzhou, Guangdong province on March 22, 2020 (Figure 1B). As of March 24, 2020, there were 427 imported cases and 3 second-generation cases originated from imported cases, one each in Beijing, Shanghai and Guangzhou (National Health Commission of the People's Republic of China). It shows that China needs to pay more attention to the control of imported cases and reflect on the measures previously taken against imported cases. Fig. 1 Three stages of China's COVID-19 epidemic (updated on March 24, 2020). (A) The first and second stages of China's COVID-19 epidemic. (B) The third stage of China's COVID-19 epidemic. Data for all cases are from World Health Organization (https://www.who.int/emergencies/diseases/novel-coronavirus-2019) and National Health Commission of the People's Republic of China (http://www.nhc.gov.cn). Fig 1 Due to the outbreak of COVID-19 in Europe and America, many overseas Chinese or ethnic Chinese had chosen to return to China where the epidemic had remained under control, many of whom were themselves COVID-19 patients without realizing that they had been infected. As a result, imported cases from outside of China appeared in early March and began to increase sharply in mid-March (Figure 1B). China is now facing increasing pressure in the face of import cases from overseas, especially in cities that a are international travel hubs such as Beijing, Shanghai and Guangzhou. On the onset of this surge in the number of overseas patients, the operational capacity of airports with high volume of international flights was not capable of efficient screening for every arrival, resulting in a large number of passenger flow jams in the airport lobby, and subsequently causing high risk of infection. Therefore, the conundrum regarding the control over overseas imported cases as well as the prevention of a second epidemic outbreak that is fast approaching is a problem that China needs to pay special attention to, especially after the first second-generation case imported from abroad had appeared. It shows that the current prevention and control measures have yet proven to be consummate. As the global epidemic continues in the outbreak period, more and more overseas Chinese citizens or ethnic Chinese, even non-Chinese, will choose to come to China to escape from the epidemic. 7 The government has shortened the processing time for immigration procedures and required all arrivals from other countries to be quarantined. However, the Chinese government needs to ensure that every overseas arrival would have passed a quarantine period of at least 14 days, and tested negative to COVID-19 before they can conduct social activities in the country, and such measures are not easy to implement. China has managed to control the outbreak of the domestic epidemic, but there are still new issues waiting for them to deal with. In addition, China's outstanding performance in the first stage of the epidemic has provided the world with valuable insights and earned two months of breathing room for the world to respond the novel virus. However, due to the lack of attention and the spread of misinformation regarding COVID-19 in many countries, the disease has seriously threatened the whole world, 4 bringing China's epidemic to the third stage. Therefore, based on the One Health model, 8 the outbreak of COVID-19 should concern all humankind, for no country can survive alone. The real victory over COVID-19 will require concerted efforts from around the globe. Declaration of Competing Interest None.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          A Novel Coronavirus from Patients with Pneumonia in China, 2019

          Summary In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily. Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans. Enhanced surveillance and further investigation are ongoing. (Funded by the National Key Research and Development Program of China and the National Major Project for Control and Prevention of Infectious Disease in China.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              COVID-19 and Italy: what next?

              Summary The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already taken on pandemic proportions, affecting over 100 countries in a matter of weeks. A global response to prepare health systems worldwide is imperative. Although containment measures in China have reduced new cases by more than 90%, this reduction is not the case elsewhere, and Italy has been particularly affected. There is now grave concern regarding the Italian national health system's capacity to effectively respond to the needs of patients who are infected and require intensive care for SARS-CoV-2 pneumonia. The percentage of patients in intensive care reported daily in Italy between March 1 and March 11, 2020, has consistently been between 9% and 11% of patients who are actively infected. The number of patients infected since Feb 21 in Italy closely follows an exponential trend. If this trend continues for 1 more week, there will be 30 000 infected patients. Intensive care units will then be at maximum capacity; up to 4000 hospital beds will be needed by mid-April, 2020. Our analysis might help political leaders and health authorities to allocate enough resources, including personnel, beds, and intensive care facilities, to manage the situation in the next few days and weeks. If the Italian outbreak follows a similar trend as in Hubei province, China, the number of newly infected patients could start to decrease within 3–4 days, departing from the exponential trend. However, this cannot currently be predicted because of differences between social distancing measures and the capacity to quickly build dedicated facilities in China.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Infect
                J. Infect
                The Journal of Infection
                The British Infection Association. Published by Elsevier Ltd.
                0163-4453
                1532-2742
                10 April 2020
                10 April 2020
                Affiliations
                [a ]College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
                [b ]National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, Guangzhou, China
                [c ]Key Laboratory of Animal Vaccine Development, Ministry of Agriculture, Guangzhou, China
                [d ]Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou, China
                Author notes
                [* ]Corresponding authors: Bin Xiang, Ph.D. xiangbin2018@ 123456126.com
                Article
                S0163-4453(20)30179-1
                10.1016/j.jinf.2020.03.048
                7151481
                32283157
                101ae899-fc0c-4eb2-a2e1-6f91c27163d1
                © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 26 March 2020
                Categories
                Article

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article